All In Biotech

Drug Trial Radar · NCT05170243

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Immunogenicity of a Single Dose of 9MW1911 Injection in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jan 21, 2022

Primary completion

Jul 3, 2022

Study completion Oct 28, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, placebo-controlled study, enrolling approximately 38 healthy adult subjects (18-65 yrs). The purpose of this study is to evaluate the safety, tolerability and PK of single ascending dose of 9MW1911 administered intravenously (IV) in healthy adult volunteers. All subjects will be followed up for safety from the time of Informed Consent through 113 days post dose.

Conditions

  • Asthma
  • COPD
  • Atopic Dermatitis

Interventions

  • 9MW1911 InjectionDrug

    Single dose intravenously on day 1

  • 9MW1911 Injection PlaceboDrug

    Single dose of matching placebo intravenously on day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event(including serious adverse event)Time frame: up to day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Public Health Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.